Angiogenesis: Something old, something new

Angiogenesis: Insights from a Systematic Overview

Volumn , Issue , 2013, Pages 1-30

  Lampri, Evangeli ^a   Ioachim, Elli ^b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b G HATZIKOSTA GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892056075     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (120)

1. Ribatti D, Vacca A, Nico B, Presta M, Roncali L. Angiogenesis: basic and clinical aspects. Ital J Anat Embryol 2003;108:1-24.
2. Carmeliet P. Manipulating angiogenesis in medicine. J Intern Med 2004;255:538-61.
3. Breier G. Angiogenesis in embryonic development--a review. Placenta 2000;21 Suppl A:S11-5.:S11-S15.
4. Breier G, Damert A, Plate KH, Risau W. Angiogenesis in embryos and ischemic diseases. Thromb Haemost 1997;78:678-83.
5. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005;438:932-6.
6. Burri PH, Hlushchuk R, Djonov V. Intussusceptive angiogenesis: its emergence, its characteristics, and its significance. Dev Dyn 2004;231:474-88.
7. Rafii S, Lyden D, Benezra R, Hattori K, Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2002;2:826-35.
8. Helisch A, Schaper W. Arteriogenesis: the development and growth of collateral arteries. Microcirculation 2003;10:83-97.
9. Kamihata H, Matsubara H, Nishiue T et al. Improvement of collateral perfusion and regional function by implantation of peripheral blood mononuclear cells into ischemic hibernating myocardium. Arterioscler Thromb Vasc Biol 2002;22:1804-10.
10. Heil M, Ziegelhoeffer T, Pipp F et al. Blood monocyte concentration is critical for enhancement of collateral artery growth. Am J Physiol Heart Circ Physiol 2002;283:H2411-H2419.
11. Cao R, Brakenhielm E, Pawliuk R et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 2003;9:604-13.
12. Iruela-Arispe ML. The Cell Biology of Angiogenesis. Angiogenesis 2005;1:1-30.
13. Djonov V, Schmid M, Tschanz SA, Burri PH. Intussusceptive angiogenesis: its role in embryonic vascular network formation. Circ Res 2000;86:286-92.
14. Choi K. The hemangioblast: a common progenitor of hematopoietic and endothelial cells. JHematother Stem Cell Res 2002;11:91-101.
15. Ribatti D, Vacca A, Nico B, Ria R, Dammacco F. Cross-talk between hematopoiesis and angiogenesis signaling pathways. Curr Mol Med 2002;2:537-43.
16. Takakura N, Watanabe T, Suenobu S et al. A role for hematopoietic stem cells in promoting angiogenesis. Cell 2000;102:199-209.
17. Shalaby F, Rossant J, Yamaguchi TP et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995;376:62-6.
18. Asahara T, Isner JM. Endothelial progenitor cells for vascular regeneration. J Hematother Stem Cell Res 2002;11:171-8.
19. Rabbany SY, Heissig B, Hattori K, Rafii S. Molecular pathways regulating mobilization of marrow-derived stem cells for tissue revascularization. Trends Mol Med 2003;9:109-17.
20. Asahara T, Murohara T, Sullivan A et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275:964-7.
21. Gehling UM, Ergun S, Schumacher U et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 2000;95:3106-12.
22. Edelberg JM, Tang L, Hattori K, Lyden D, Rafii S. Young adult bone marrow-derived endothelial precursor cells restore aging-impaired cardiac angiogenic function. Circ Res 2002;90:E89-E93.
23. Takahashi T, Kalka C, Masuda H et al. Ischemia-and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999;5:434-8.
24. Vasa M, Fichtlscherer S, Aicher A et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001;89:E1-E7.
25. Shintani S, Murohara T, Ikeda H et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 2001;103:2776-9.
26. Hill JM, Zalos G, Halcox JP et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. NEngl J Med 2003;348:593-600.
27. Peichev M, Naiyer AJ, Pereira D et al. Expression of VEGFR-2 and AC133 by circulating human CD34+ cells identifies a population of functional endothelial precursors. Blood 2000;95:952-8.
28. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 2000;105:71-7.
29. Yamaguchi J, Kusano KF, Masuo O et al. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation 2003;107:1322-8.
30. Iwaguro H, Yamaguchi J, Kalka C et al. Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation 2002;105:732-8.
31. Hattori K, Dias S, Heissig B et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med 2001;193:1005-14.
32. Rehman J, Li J, Orschell CM, March KL. Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 2003;107:1164-9.
33. Carmeliet P, Luttun A. The emerging role of the bone marrow-derived stem cells in therapeutic angiogenesis. Thromb Haemost 2001;86:289-97.
34. Minasi MG, Riminucci M, De Angelis L et al. The meso-angioblast: a multipotent, self-renewing cell that originates from the dorsal aorta and differentiates into most mesodermal tissues. Development 2002;129:2773-83.
35. Reyes M, Dudek A, Jahagirdar B, Koodie L, Marker PH, Verfaillie CM. Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest 2002;109:337-46.
36. Hirschi K, Goodell M. Common origins of blood and blood vessels in adults? Differentiation 2001;68:186-92.
37. Gerhardt H, Golding M, Fruttiger M et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 2003;161:1163-77.
38. Phng LK, Gerhardt H. Angiogenesis: a team effort coordinated by notch. Dev Cell 2009;16:196-208.
39. Iruela-Arispe ML, Davis GE. Cellular and molecular mechanisms of vascular lumen formation. Dev Cell 2009;16:222-31.
40. Dejana E, Tournier-Lasserve E, Weinstein BM. The control of vascular integrity by endothelial cell junctions: molecular basis and pathological implications. Dev Cell 2009;16:209-21.
41. Claxton S, Fruttiger M. Periodic Delta-like 4 expression in developing retinal arteries. Gene Expr Patterns 2004;5:123-7.
42. Lu X, Le Noble F, Yuan L et al. The netrin receptor UNC5B mediates guidance events controlling morphogenesis of the vascular system. Nature 2004;432:179-86.
43. Siekmann AF, Lawson ND. Notch signalling and the regulation of angiogenesis. Cell Adh Migr 2007;1:104-6.
44. Tammela T, Zarkada G, Wallgard E et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008;454:656-60.
45. Leslie JD, Ariza-McNaughton L, Bermange AL, McAdow R, Johnson SL, Lewis J. Endothelial signalling by the Notch ligand Delta-like 4 restricts angiogenesis. Development 2007;134:839-44.
46. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003;9:685-93.
47. Jones EA, le Noble F, Eichmann A. What determines blood vessel structure? Genetic prespecification vs. hemodynamics. Physiology Bethesda 2006;21:388-95.
48. Djonov VG, Kurz H, Burri PH. Optimality in the developing vascular system: branching remodeling by means of intussusception as an efficient adaptation mechanism. Dev Dyn 2002;224:391-402.
49. le Noble F, Fleury V, Pries A, Corvol P, Eichmann A, Reneman RS. Control of arterial branching morphogenesis in embryogenesis: go with the flow. Cardiovasc Res 2005;65:619-28.
50. Gittenberger-De Groot AC, DeRuiter MC, Bergwerff M, Poelmann RE. Smooth muscle cell origin and its relation to heterogeneity in development and disease. Arterioscler Thromb Vasc Biol 1999;19:1589-94.
51. Vrancken Peeters MP, Gittenberger-de Groot AC, Mentink MM, Hungerford JE, Little CD, Poelmann RE. Differences in development of coronary arteries and veins. Cardiovasc Res 1997;36:101-10.
52. Simper D, Stalboerger PG, Panetta CJ, Wang S, Caplice NM. Smooth muscle progenitor cells in human blood. Circulation 2002;106:1199-204.
53. Frid MG, Kale VA, Stenmark KR. Mature vascular endothelium can give rise to smooth muscle cells via endothelial-mesenchymal transdifferentiation: in vitro analysis. Circ Res 2002;90:1189-96.
54. Jain RK, Munn LL. Leaky vessels? Call Ang1! Nat Med 2000;6:131-2.
55. Visconti RP, Richardson CD, Sato TN. Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor VEGF. Proc Natl Acad Sci USA 2002;99:8219-24.
56. Ruoslahti E. Specialization of tumour vasculature. Nat Rev Cancer 2002;2:83-90.
57. Lawson ND, Vogel AM, Weinstein BM. sonic hedgehog and vascular endothelial growth factor act upstream of the Notch pathway during arterial endothelial differentiation. Dev Cell 2002;3:127-36.
58. Iso T, Hamamori Y, Kedes L. Notch signaling in vascular development. Arterioscler Thromb Vasc Biol 2003;23:543-53.
59. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003;9:677-84.
60. Yu TW, Bargmann CI. Dynamic regulation of axon guidance. Nat Neurosci 2001;4(Suppl: 1)169-76.
61. Shima DT, Mailhos C. Vascular developmental biology: getting nervous. Curr Opin Genet Dev 2000;10:536-42.
62. Eichmann A, Le Noble F, Autiero M, Carmeliet P. Guidance of vascular and neural network formation. Curr Opin Neurobiol 2005;15:108-15.
63. Weinstein BM. Vessels and nerves: marching to the same tune. Cell 2005;120:299-302.
64. Ruhrberg C, Gerhardt H, Golding M et al. Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev 2002;16:2684-98.
65. Wang HU, Chen ZF, Anderson DJ. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 1998;93:741-53.
66. Zhang XQ, Takakura N, Oike Y et al. Stromal cells expressing ephrin-B2 promote the growth and sprouting of ephrin-B2+ endothelial cells. Blood 2001;98:1028-37.
67. Gerety SS, Wang HU, Chen ZF, Anderson DJ. Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol Cell 1999;4:403-14.
68. Adams RH, Wilkinson GA, Weiss C et al. Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev 1999;13:295-306.
69. Oliver G, Detmar M. The rediscovery of the lymphatic system: old and new insights into the development and biological function of the lymphatic vasculature. Genes Dev 2002;16:773-83.
70. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
71. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int 1999;56:794-814.
72. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6:389-95.
73. Conway EM, Collen D, Carmeliet P. Molecular mechanisms of blood vessel growth. Cardiovasc Res 2001;49:507-21.
74. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25.
75. Gluzman-Poltorak Z, Cohen T, Herzog Y, Neufeld G. Neuropilin-2 is a receptor for the vascular endothelial growth factor VEGF forms VEGF-145 and VEGF-165. J Biol Chem 2000;275:29922.
76. Gluzman-Poltorak Z, Cohen T, Shibuya M, Neufeld G. Vascular endothelial growth factor receptor-1 and neuropilin-2 form complexes. J Biol Chem 2001;276:18688-94.
77. Park JE, Chen HH, Winer J, Houck KA, Ferrara N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 1994 14;269:25646-54.
78. Autiero M, Waltenberger J, Communi D et al. Role of PlGF in the intra-and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 2003;9:936-43.
79. Luttun A, Tjwa M, Moons L et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002;8:831-40.
80. Carmeliet P, Moons L, Luttun A et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001;7:575-83.
81. Pepper MS. Extracellular proteolysis and angiogenesis. Thromb Haemost 2001;86:346-55.
82. Jackson C. Matrix metalloproteinases and angiogenesis. Curr Opin Nephrol Hypertens 2002;11:295-9.
83. Luttun A, Dewerchin M, Collen D, Carmeliet P. The role of proteinases in angiogenesis, heart development, restenosis, atherosclerosis, myocardial ischemia, and stroke: insights from genetic studies. Curr Atheroscler Rep 2000;2:407-16.
84. Yousef GM, Diamandis EP. Expanded human tissue kallikrein family--a novel panel of cancer biomarkers. Tumour Biol 2002;23:185-92.
85. Miao RQ, Agata J, Chao L, Chao J. Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood 2002;100:3245-52.
86. Bergers G, Brekken R, McMahon G et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737-44.
87. Hynes RO. A reevaluation of integrins as regulators of angiogenesis. Nat Med 2002;8:918-21.
88. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer 2002;2:91-100.
89. Senger DR, Perruzzi CA, Streit M, Koteliansky VE, de Fougerolles AR, Detmar M. The alpha1beta1 and alpha2beta1 integrins provide critical support for vascular endothelial growth factor signaling, endothelial cell migration, and tumor angiogenesis. Am J Pathol 2002;160:195-204.
90. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science 1999;284:770-6.
91. Gridley T. Notch signaling in vertebrate development and disease. Mol Cell Neurosci 1997;9:103-8.
92. Sainson RC, Aoto J, Nakatsu MN et al. Cell-autonomous notch signaling regulates endothelial cell branching and proliferation during vascular tubulogenesis. FASEB J 2005;19:1027-9.
93. Davis S, Aldrich TH, Jones PF et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996;87:1161-9.
94. Thurston G, Rudge JS, Ioffe E et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 2000;6:460-3.
95. Xu Y, Yu Q. Angiopoietin-1, unlike angiopoietin-2, is incorporated into the extracellular matrix via its linker peptide region. J Biol Chem 2001;276:34990-8.
96. Carlson TR, Feng Y, Maisonpierre PC, Mrksich M, Morla AO. Direct cell adhesion to the angiopoietins mediated by integrins. J Biol Chem 2001;276:26516-25.
97. Gale NW, Yancopoulos GD. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 1999;13:1055-66.
98. Maisonpierre PC, Suri C, Jones PF et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997;277:55-60.
99. Gale NW, Thurston G, Hackett SF et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell 2002;3:411-23.
100. Akhurst RJ. A sweet link between TGFbeta and vascular disease? Nat Genet 2006;38:400-1.
101. Chen YG, Hata A, Lo RS et al. Determinants of specificity in TGF-beta signal transduction. Genes Dev 1998;12:2144-52.
102. Lamouille S, Mallet C, Feige JJ, Bailly S. Activin receptor-like kinase 1 is implicated in the maturation phase of angiogenesis. Blood 2002;100:4495-501.
103. Oh SP, Seki T, Goss KA et al. Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci U S A 2000;97:2626-31.
104. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J 2002;21:1743-53.
105. Taylor LM, Khachigian LM. Induction of platelet-derived growth factor B-chain expression by transforming growth factor-beta involves transactivation by Smads. J Biol Chem 2000;275:16709-16.
106. Betsholtz C, Karlsson L, Lindahl P. Developmental roles of platelet-derived growth factors. Bioessays 2001;23:494-507.
107. Cao R, Brakenhielm E, Li X et al. Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF family, involves activation of PDGFR-alphaalpha and-alphabeta receptors. FASEB J 2002;16:1575-83.
108. Li H, Fredriksson L, Li X, Eriksson U. PDGF-D is a potent transforming and angiogenic growth factor. Oncogene 2003;22:1501-10.
109. Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol 2001;61:253-70.
110. Duarte M, Filho AL, Schmitt FC. Angiogenesis, haemostasis and cancer: new paradigms and old concerns. J Bras Patol Med Lab 2007;43:441-9.
111. Bernardini G, Ribatti D, Spinetti G et al. Analysis of the role of chemokines in angiogenesis. J Immunol Methods 2003;273:83-101.
112. Lewis JS, Lee JA, Underwood JC, Harris AL, Lewis CE. Macrophage responses to hypoxia: relevance to disease mechanisms. J Leukoc Biol 1999;66:889-900.
113. Ohm JE, Carbone DP. Immune dysfunction in cancer patients. Oncology Williston Park 2002;16:11-8.
114. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
115. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002;2:795-803.
116. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993;90:10705-9.
117. D'Amore PA, Ng YS. Tales of the cryptic: unveiling more angiogenesis inhibitors. Trends Mol Med 2002;8:313-5.
118. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-39.
119. Man S, Bocci G, Francia G et al. Antitumor effects in mice of low-dose metronomic cyclophosphamide administered continuously through the drinking water. Cancer Res 2002;62:2731-5.
120. Brekken RA, Overholser JP, Stastny VA, Waltenberger J, Minna JD, Thorpe PE. Selective inhibition of vascular endothelial growth factor VEGF receptor 2 KDR/Flk-1 activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 2000;60:5117-24.